drugset
drugset / Trial / NCT05444556

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

NCT05444556 ↗

Phase 1 Completed 113 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

The main purpose of this study is to evaluate the effect of imlunestrant on repaglinide, omeprazole and dextromethorphan, and rosuvastatin and digoxin. The study will also investigate the effect of quinidine on imlunestrant in female healthy participants of non-childbearing potential. The safety and tolerability of imlunestrant will be investigated in female healthy participants of non-childbearing potential. The study will last approximately up to 32 days for each participant excluding the screening period.

Timeline

Start
2022-07-07
Primary completion
2022-11-02
Completion
2022-11-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dextromethorphan Unknown 30 mg Oral
Subject Digoxin Other / unclassified 0.25 mg Oral
Subject Imlunestrant Small molecule 400 mg Oral
Subject Imlunestrant Small molecule 800 mg Oral
Subject Omeprazole Other / unclassified 20 mg Oral
Subject Quinidine Small molecule 200 mg Oral
Subject Repaglinide Small molecule 0.5 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral

Indications

No indication recorded.